← Eichor
Condition: Recurrent And Refractory Diffuse Large B Cell Lymphoma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Recurrent And Refractory Diffuse Large B Cell Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 · 7 location(s) · AIDS Malignancy Consortium · NCT05077527Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT05672251Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Phase 2 · 3 location(s) · Aseel Alsouqi · NCT05873712A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Accutar Biotechnology Inc · NCT05780034Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.
Phase 2 · 18 location(s) · Fondazione Italiana Linfomi - ETS · NCT04915248Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Phase 1 · 9 location(s) · National Cancer Institute (NCI) · NCT05272384Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Le
Phase 2 · 4 location(s) · Mayo Clinic · NCT03418038Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1 · 9 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT06980116Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade
Phase 2 · 7 location(s) · Istituto Clinico Humanitas · NCT06918912Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antige
Phase 2 · 1 location(s) · University of California, Davis · NCT06854159A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Ref
Phase 1 · 1 location(s) · GenomeFrontier Therapeutics TW Co., Ltd. · NCT06703892Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/Phase 2 · 34 location(s) · Lyell Immunopharma, Inc. · NCT05826535Immunotherapy in Lymphoma
Phase N/A · 2 location(s) · Sung-Soo Park · NCT06796517Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before C
Phase 2 · 7 location(s) · Mayo Clinic · NCT06834373Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Phase 1 · 1 location(s) · Lapo Alinari · NCT05755087Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Phase 1 · 1 location(s) · Medical College of Wisconsin · NCT055449683'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Rel
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06859008A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcita
Phase 2 · 53 location(s) · Hoffmann-La Roche · NCT06806033Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07332507Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relaps
Phase 2 · 15 location(s) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ó · NCT07126236Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Phase 2 · 1 location(s) · Daihong Liu · NCT07489989Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · 87 location(s) · SWOG Cancer Research Network · NCT05633615Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT07365306Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
Phase 2 · 1 location(s) · University of Washington · NCT06784726Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Phase 1/Phase 2 · 2 location(s) · Yazeed Sawalha · NCT06536049Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Phase 1 · 2 location(s) · Timothy Voorhees · NCT06672705A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06086197
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.